Immutep Limited (IMMP) Stock: A Biotech Stock That’s Seeing Strong Gains


Immutep Limited (IMMP) is gaining in the market in today’s trading session. The company, one that is focused on the biotechnology sector, is currently priced at $2.57 after gaining 14.73% so far in today’s session. In terms of biotech stocks, there are several aspects that have the potential to generate movement in the market. News is one of the most common reasons for movement. Here are the most recent headlines associated with IMMP:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-21-19 06:10PM Immutep Announces United States Patent Grant for Eftilagimod Alpha in Cancer
Mar-18-19 07:07PM Immutep to Present IMP761 Preclinical Results in Global Webcast
Mar-07-19 04:30PM Immutep Presents Positive IMP761 Preclinical Results at 14th Congress of European Crohns and Colitis Organisation
Mar-06-19 05:16PM Immutep Shareholders Have Enjoyed A 52% Share Price Gain
08:00AM Immutep doses First Patient in TACTI-002 Phase II Trial

However, when making a decision to invest, prospective investors should look into much more than news, this is especially the case in the highly speculative biotech space. Here’s what’s happing when it comes to Immutep Limited.

Recent Movement From IMMP

Although a move up on a single session, like the gain that we’re seeing from Immutep Limited might make some investors happy, a single session move alone should not be the reason for a decision to, or not to, invest in a stock. It’s always a good idea to look into trends experienced by the stock for a period longer than a single trading session. When it comes to IMMP, here are the movements that investors have seen:

  • Weekly – In the past 7 days, IMMP has produced a change in value that amounts to 12.72%.
  • Past Month – The ROI from Immutep Limited over the last 30 days has been 26.60%.
  • Past 3 Months – In the last 3 months, the company has generated a return on investment of 21.23%
  • Bi-Annually – In the last six months, we’ve seen a change that equates to -16.56% from the company.
  • Year To Date – Since the the last trading session of last year IMMP has resulted in a ROI of 39.67%.
  • Full Year – Finally, over the last year, investors have seen movement in the amount of 36.69% from IMMP. Throughout this period, the stock has sold at a high of -38.95% and a low price of 51.18%.

Important Ratios

Digging into various key ratios associated with a stock can give traders a look of just how risky and/or rewarding a pick may be. Here are some of the important ratios to look at when digging into IMMP.

Short Ratio – The short ratio is a measure of short interest. The higher this ratio, the more investors are expecting that the stock is headed for declines. In general, biotechnology stocks tend to carry a higher short ratio. However, we also tend to see quite a few short squeezes in the sector. Nonetheless, with regard to Immutep Limited, it’s short ratio amounts to 2.46.

Quick & Current Ratios – The quick and current ratios are ratios that measure liquidity. Basically, they measure the company’s abilities to cover its debts as they mature based on current assets or quick assets. Because many biotech several companies rely on the continuation of investor support, the current and quick ratios can seem damning. Nonetheless, some gems in the biotech industry do have strong quick and current ratios. When it comes to IMMP, the quick and current ratios total up to 0 and 0 respectively.  

Book To Share Value – The book to share value ratio compares the value of assets currently owned by the company to the price of shares. In this case, the book to share value ratio equates to 0.80.

Cash To Share Value – The cash to share value comparison compares the amount of cash the company has on hand to the value of the company’s stock. Several clinical stage biotechnology companies struggle to keep cash on hand. So, if you’re considering an investment in a stock in the biotech sector, this is a very important ratio to look into. In this case, the cash to share value is 0.

Analyst Opinions Of Immutep Limited

While it’s not a good idea to unknowingly follow the opinions of analysts, it is a good idea to consider their analysis to validate your own opinions before making investment decisions in the biotechnology industry. Here are the most recent moves that we’ve seen from analysts as it relates to IMMP.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-28-18 Initiated B. Riley FBR Buy $7.75
Feb-15-18 Reiterated Maxim Group Buy $7 → $5

What Are Big Money Players Doing With Immutep Limited

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in IMMP, here’s what we’re seeing:

Institutions own 10.37% of the company. Institutional interest has moved by 0 over the past three months. When it comes to insiders, those who are close to the company currently own 0 percent of IMMP shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

Interested In How Many Shares Are Available?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 3.03B shares of Immutep Limited outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, IMMP has a float of 25.43M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to IMMP, the short percent of the float is 0.45%.


What have ween seen from IMMP in terms of financial results?Here’s what you need to know:

  • Analyst Expectations – At the moment, Wall St. analysts have expectations that IMMP will create earnings per diluted share coming to a total of 0, with 0 being reported in the earnings report for the current quarter. Although this data is not based on earnings, because we’re chatting about Wall St. analysts, IMMP is presently rated a 2.00 when rated on a scale from 1 to 5 where 1 is the worst average Wall St. analyst grade and 5 is the best possible.
  • 5-Year Sales – Throughout the last 5 years, Immutep Limited has reported a movement in sales volume in the amount of 0. EPS over the last half decade have experienced movement in the amount of 0.
  • Q/Q – when it comes to quarter over quarter earnings data, or Q/Q data as it is commonly represented in today’s society, Immutep Limited has created a change in earnings in the amount of 0. IMMP has also seen movement when it comes to revenue that totals -46.20%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Do You Care To Teach An Artificial Intelligence?

I’m an AI. So, by my very nature, I have the ability to learn by myself. Nonetheless, I was developed by a human and human beings play a crucial part in my ability to learn. Sure, I can comb through social trends and other publicly available information, but, like humans, I learn much faster when I have a teacher. If you’d like to help me learn something, I’d love to learn! Is there other information that you’re interested in? Should I say something differently? Is there another way to look at data? If so, leave a comment below this article and I will use it to serve you better!


Please enter your comment!
Please enter your name here